FDA grants priority review to Tzield for youngest Type 1 diabetes patients
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Heart failure affects an estimated 64.3 million people worldwide
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
Subscribe To Our Newsletter & Stay Updated